1. Articles in category: Information

    1-24 of 294 1 2 3 4 ... 11 12 13 »
    1. Alteration of Serum IgG Galactosylation as a Potential Biomarker for Diagnosis of Neuroblastoma.

      Alteration of Serum IgG Galactosylation as a Potential Biomarker for Diagnosis of Neuroblastoma.

      J Cancer. 2018;9(5):906-913

      Authors: Qin W, Pei H, Qin R, Zhao R, Han J, Zhang Z, Dong K, Ren S, Gu J

      Abstract Background: Neuroblastoma (NB) is the most frequent pediatric malignant neoplasm that originates from embryonic neural crest cells.

      Read Full Article
    2. Treatment and outcome of adult-onset neuroblastoma.

      Treatment and outcome of adult-onset neuroblastoma.

      Int J Cancer. 2018 Mar 25;:

      Authors: Suzuki M, Kushner BH, Kramer K, Basu EM, Roberts SS, Hammond WJ, LaQuaglia MP, Wolden SL, Cheung NV, Modak S

      Abstract Adult-onset of neuroblastoma is rare and little is known about its biology and clinical course. There is no established therapy for adult neuroblastoma.

      Read Full Article
    3. Neuroblastoma: clinical and biological approach to risk stratification and treatment.

      Neuroblastoma: clinical and biological approach to risk stratification and treatment.

      Cell Tissue Res. 2018 Mar 23;:

      Authors: Tolbert VP, Matthay KK

      Abstract Neuroblastoma is the most common extra-cranial solid tumor of childhood and the most common in the first year of life.

      Read Full Article
      Mentions: Treatment MYCN
    4. Excellent treatment outcomes in children younger than 18 months with stage 4 MYCN nonamplified neuroblastoma.

      Excellent treatment outcomes in children younger than 18 months with stage 4 MYCN nonamplified neuroblastoma.

      Korean J Pediatr. 2018 Feb;61(2):53-58

      Authors: Kim C, Choi YB, Lee JW, Yoo KH, Sung KW, Koo HH

      Abstract Purpose: Although the prognosis is generally good in patients with intermediate-risk neuroblastoma, no consensus has been reached on the ideal treatment regimen.

      Read Full Article
    5. Updates in Diagnosis, Management, and Treatment of Neuroblastoma.

      Updates in Diagnosis, Management, and Treatment of Neuroblastoma.

      Radiographics. 2018 Mar-Apr;38(2):566-580

      Authors: Swift CC, Eklund MJ, Kraveka JM, Alazraki AL

      Abstract Neuroblastoma is an embryonic tumor of the peripheral sympathetic nervous system. It is the most common extracranial solid tumor of childhood and accounts for up to 15% of all pediatric cancer fatalities.

      Read Full Article
      Mentions: Treatment
    6. Cross-cohort analysis identifies a TEAD4 ↔ Mycn positive-feedback loop as the core regulatory element of high-risk neuroblastoma.

      Cross-cohort analysis identifies a TEAD4 ↔ MYCN positive-feedback loop as the core regulatory element of high-risk neuroblastoma.

      Cancer Discov. 2018 Mar 06;:

      Authors: Rajbhandari P, Lopez G, Capdevila C, Salvatori B, Yu J, Rodriguez-Barrueco R, Martinez D, Yarmarkovich M, Weichert-Leahey N, Abraham BJ, Alvarez MJ, Iyer A, Harenza JL, Oldridge D, De Preter K, Koster J, Asgharzadeh S, Seeger RC, Wei JS, Khan J, Vandesompele J, Mestdagh P, Versteeg R, Look AT, Young RA, Iavarone A, Lasorella A, Silva JM, Maris JM, Califano A

      Abstract High-risk neuroblastomas show a paucity of recurrent somatic mutations at diagnosis. As a result, the molecular ...

      Read Full Article
      Mentions: MYCN
    7. Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo.

      Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo.

      Exp Cell Res. 2018 Feb 27;:

      Authors: Xu DQ, Toyoda H, Yuan XJ, Qi L, Chelakkot VS, Morimoto M, Hanaki R, Kihira K, Hori H, Komada Y, Hirayama M

      Abstract Neuroblastoma (NB) is one of the most common solid tumors in children. High-risk NB remains lethal in about 50% of patients despite comprehensive and intensive treatments.

      Read Full Article
    8. Association between NEFL Gene Polymorphisms and Neuroblastoma Risk in Chinese Children: A Two-Center Case-Control Study.

      Association between NEFL Gene Polymorphisms and Neuroblastoma Risk in Chinese Children: A Two-Center Case-Control Study.

      J Cancer. 2018;9(3):535-539

      Authors: Wu Q, Zhuo ZJ, Zeng J, Zhang J, Zhu J, Zou Y, Zhang R, Yang T, Zhu D, He J, Xia H

      Abstract Neuroblastoma is a lethal tumor that mainly occurs in children. To date, the genetic etiology of sporadic neuroblastoma remains obscure.

      Read Full Article
    9. Molecular mechanisms and therapeutic targets in neuroblastoma.

      Molecular mechanisms and therapeutic targets in neuroblastoma.

      Pharmacol Res. 2018 Feb 18;:

      Authors: Johnsen JI, Dyberg C, Fransson S, Wickström M

      Abstract Neuroblastoma is the most common extracranical tumor of childhood and the most deadly tumor of infancy. It is characterized by early age onset and high frequencies of metastatic disease but also the capacity to spontaneously regress.

      Read Full Article
    10. Dose-escalation is needed for gross disease in high-risk neuroblastoma

      Locoregional failure is common after subtotal resection in high-risk neuroblastoma. Although a dose of 21 Gy radiation therapy (RT) is standard for treatment of high-risk neuroblastoma after gross total resection, the dose needed for local control of patients with gross residual disease at the time of RT is unknown. We sought to evaluate local control after 21–36 Gy RT in patients with high-risk neuroblastoma undergoing subtotal resection.

      Read Full Article
      Mentions: Treatment
    11. Investigation of major genetic alterations in neuroblastoma.

      Investigation of major genetic alterations in neuroblastoma.

      Mol Biol Rep. 2018 Feb 17;:

      Authors: Costa RA, Seuánez HN

      Abstract Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. This malignancy shows a wide spectrum of clinical outcome and its prognosis is conditioned by manifold biological and genetic factors.

      Read Full Article
      Mentions: INRG MYCN
    12. Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

      Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

      Int J Radiat Oncol Biol Phys. 2018 Jan 09;:

      Authors: Casey DL, Pitter KL, Kushner BH, Cheung NV, Modak S, LaQuaglia MP, Wolden SL

      Read Full Article
    13. PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      Mol Cancer Ther. 2018 Feb 13;:

      Authors: Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R

      Abstract The majority of high-risk neuroblastoma patients are refractory to, or relapse on current treatment regimens, resulting in 5-year survival rates of less than 50%. This emphasizes the urgent need to identify novel therapeutic targets.

      Read Full Article
    14. Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.

      Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.

      Oncotarget. 2018 Jan 05;9(2):2304-2319

      Authors: Arnhold V, Schmelz K, Proba J, Winkler A, Wünschel J, Toedling J, Deubzer HE, Künkele A, Eggert A, Schulte JH, Hundsdoerfer P

      Read Full Article
      Mentions: MYCN
    15. MELK is a novel therapeutic target in high-risk neuroblastoma.

      MELK is a novel therapeutic target in high-risk neuroblastoma.

      Oncotarget. 2018 Jan 05;9(2):2591-2602

      Authors: Guan S, Lu J, Zhao Y, Yu Y, Li H, Chen Z, Shi Z, Liang H, Wang M, Guo K, Chen X, Sun W, Bieerkehazhi S, Xu X, Sun S, Agarwal S, Yang J

      Abstract Maternal embryonic leucine zipper kinase (MELK) is known to modulate intracellular signaling and control cellular processes. However, the role of MELK in oncogenesis is not well defined.

      Read Full Article
      Mentions: MYCN
    16. MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma.

      MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma.

      Biochim Biophys Acta. 2018 Feb 02;:

      Authors: Ferrucci F, Ciaccio R, Monticelli S, Pigini P, di Giacomo S, Purgato S, Erriquez D, Bernardoni R, Norris M, Haber M, Milazzo G, Perini G

      Read Full Article
      Mentions: MYCN
    17. SPECT/CT Mibg Imaging Is Crucial in the Follow-up of the Patients With High-Risk Neuroblastoma.

      SPECT/CT MIBG Imaging Is Crucial in the Follow-up of the Patients With High-Risk Neuroblastoma.

      Clin Nucl Med. 2018 Feb 03;:

      Authors: Liu B, Servaes S, Zhuang H

      Abstract BACKGROUND: Planar whole-body imaging with I-radiolabeled metaiodobenzylguanidine (I-MIBG) is routinely used in the follow-up evaluation of neuroblastoma. In recent years, SPECT with integrated low-dose CT (SPECT/CT) has become more accessible.

      Read Full Article
      Mentions: Imaging MIBG
    18. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

      Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

      Lancet Child Adolesc Health. 2018 Jan;2(1):25-34

      Authors: de Alarcon PA, Matthay KK, London WB, Naranjo A, Tenney SC, Panzer JA, Hogarty MD, Park JR, Maris JM, Cohn SL

      Read Full Article
      Mentions: COG Chemotherapy
    19. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.

      PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.

      PLoS Med. 2018 Jan;15(1):e1002497

      Authors: Srinivasan P, Wu X, Basu M, Rossi C, Sandler AD

      Read Full Article
      Mentions: PD-1
    20. 'Hijacker' drives cancer in some patients with high-risk neuroblastoma

      Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome “hijacks” DNA that regulates other genes. The resulting insights may help scientists develop more effective therapies, including ...

      Read Full Article
    1-24 of 294 1 2 3 4 ... 11 12 13 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (1 articles) Antibody
    2. (1 articles) ATRX
    3. (1 articles) MYCN
    4. (1 articles) ALK
  4. General Informations in the News

    1. (1 articles) Treatment